Human muscle in gene edited pigs for treatment of volumetric muscle loss

Sarah M Greising; Joshua I Weiner; Daniel J Garry; David H Sachs; Mary G Garry

doi:10.3389/fgene.2022.948496

Human muscle in gene edited pigs for treatment of volumetric muscle loss

Front Genet. 2022 Jul 25:13:948496. doi: 10.3389/fgene.2022.948496. eCollection 2022.

Authors

Sarah M Greising¹, Joshua I Weiner², Daniel J Garry^{3

4

5

6}, David H Sachs^{2

7}, Mary G Garry^{3

4

5

6}

Affiliations

¹ School of Kinesiology, University of Minnesota, Minneapolis, MN, United States.
² Departments of Surgery, Columbia Center for Translations Immunology, College of Physicians and Surgeons, Columbia University, New York, NY, United States.
³ Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN, United States.
⁴ Stem Cell Institute, University of Minnesota, Minneapolis, MN, United States.
⁵ Lillehei Heart Institute, University of Minnesota, Minneapolis, MN, United States.
⁶ NorthStar Genomics, Eagan, MN, United States.
⁷ Department of Surgery, Massachusetts General Hospital, Boston, MA, United States.

Abstract

Focusing on complex extremity trauma and volumetric muscle loss (VML) injuries, this review highlights: 1) the current pathophysiologic limitations of the injury sequela; 2) the gene editing strategy of the pig as a model that provides a novel treatment approach; 3) the notion that human skeletal muscle derived from gene edited, humanized pigs provides a groundbreaking treatment option; and 4) the impact of this technologic platform and how it will advance to far more multifaceted applications. This review seeks to shed insights on a novel treatment option using gene edited pigs as a platform which is necessary to overcome the clinical challenges and limitations in the field.

Keywords: blastocyst complementation; human animal chimeras; skeletal muscle function; somatic cell nuclear transfer; xenotransplantation.

Publication types

Review